Slide 1: Driving Home Health Admissions
Driving Home Health Admissions Early Proof Points Demonstrating Tangible Results of Our Strategy Re-designed Business Development Strategy Home Health Consolidated Admissions (YoY Growth) 1 @ @ @ @ @ @ Continued Progress in Payor Innovation Contracts Strategy + Increased favorable payor contracts +
Slide 2: Increasing Hospice Census and Admissions
Increasing Hospice Census and Admissions Enhancing our Hospice Operating Model ... ... Leading to Tangible Results Monthly Census Trend‘ Case + New staffing model in place as of Q3 of 2023 Management Staffing + Staffing constraints eliminated 7 3,520 Model + Recruitment and retention improvements [|
Slide 3: Supplemental Myth/Facts (1/5)
enhabit Supplemental Myth/Facts (1/5) Hone toe This is false. Over the past year, the Board and management team have engaged with AREX every time AREX has asked for a meeting. AREX has not requested a meeting with any members of the Board since Enhabit's termination of the strategic review in May. B
Slide 4: Supplemental Myth/Facts (2/5)
enhabit Supplemental Myth/Facts (2/5) Hone toe Myth: AREX’s Narrat The Facts AREX is not targeting the CEO The Board seems ignorant of the serious risk that Enhabit’s leverage creates for the Company Enhabit Home Health & Hospice = => While AREX is not seeking to unseat Ms. Jacobsmeyer from the Boar
Slide 5: Supplemental Myth/Facts (3/5)
enhabit Supplemental Myth/Facts (3/5) Hone toe Enrollment growth rates for Medicare Advantage have declined since Q3 2021 and therefore Enhabit could not have been disadvantaged by trends in Medicare Advantage enrollment The inability to manage the ongoing payor mix shift is directly responsible for
Slide 6: Supplemental Myth/Facts (4/5)
Supplemental Myth/Facts (4/5) Drastic changes in the incentives and directives given to local home health branches after the implementation of a national contract in May 2023 drove a significant loss of Medicare FFS market share The Board has continually refused to upgrade itself by adding directors
Slide 7: Supplemental Myth/Facts (5/5)
enhabit Supplemental Myth/Facts (5/5) Hone toe Myth: AREX’s Narrat The Facts Enhabit is cherry-picking time periods and peer groups to mislead investors about Total Shareholder Return (TSR) performance Enhabit Home Health & Hospice => Both AREX’s and our TSR comparisons support exactly what Enhabit
Slide 8: Forward-Looking Statements
Forward-Looking Statements Statements contained in this presentation which are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All forward-looking information speaks only as of the date hereof, and Enhabit undertakes no